Anuh Pharma Limited, a prominent player in the pharmaceutical industry, has announced its financial results for the first quarter, alongside a key executive appointment.

Financial Performance

The company reported a significant increase in revenue from operations for Q1, reaching Rs 18,647.94 lakhs, up from Rs 13,790.83 lakhs in the same quarter of the previous year, marking a 35.2% year-over-year growth. However, the profit after tax saw a slight decline, standing at Rs 830.12 lakhs compared to Rs 950.91 lakhs in the corresponding quarter last year.

Key financial highlights for Q1:

The company's EBITDA margin for the quarter stood at 7.34%, showing a decrease from 10.36% in the same quarter of the previous year. This decline in profitability metrics despite revenue growth suggests increased operational costs or market pressures during the quarter.

Appointment of Chief Marketing Officer

In a strategic move to strengthen its leadership team, Anuh Pharma's Board of Directors has approved the appointment of Mr. Vinayak Shenoy as the Chief Marketing Officer, effective August 11, 2025. Mr. Shenoy brings over 15 years of experience in APIs and Intermediates, with expertise spanning global markets including the USA, Europe, CIS, SEA, LATAM, and India.

Mr. Shenoy's appointment is expected to bolster Anuh Pharma's market presence and strategic growth initiatives. His extensive background in business development and sales, coupled with his proven track record in key account management and market-entry strategies, aligns well with the company's expansion goals.

Looking Ahead

As Anuh Pharma navigates the evolving pharmaceutical landscape, the combination of revenue growth and strategic appointments suggests a focus on both immediate performance and long-term market positioning. Investors and industry observers will likely keep a close watch on how these developments translate into sustained financial performance and market share growth in the coming quarters.

The company continues to operate in the Bulk drug and Chemicals segment, as identified in its financial reporting, maintaining its focus on its core business areas.

Anuh Pharma Limited remains committed to creating value for its stakeholders through operational excellence and strategic initiatives in the pharmaceutical sector.

Anuh Pharma Limited has taken a significant step in expanding its production capabilities with the inauguration of a new manufacturing facility in Tarapur, located in Maharashtra's Palghar district. The company announced this development in a recent regulatory filing, marking a notable expansion in its manufacturing infrastructure.

New Facility Details

The newly inaugurated Manufacturing Block INT-1A is situated at E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, Boisar, District Palghar. The facility was officially inaugurated on July 15, 2025, and is expected to commence operations within the same month.

Capacity Enhancement

The addition of this new manufacturing block is set to substantially boost Anuh Pharma's production capacity:

This expansion represents a notable increase of about 9% in the company's annual production capacity.

Infrastructure Improvements

Beyond the increase in production volume, the new INT-1A block includes the installation of an additional 40 KL of reactor capacity. This enhancement is expected to strengthen Anuh Pharma's infrastructure and better position the company to meet growing market demands in the pharmaceutical sector.

Strategic Implications

The expansion of manufacturing capabilities suggests that Anuh Pharma is positioning itself for growth in the pharmaceutical market. By increasing its production capacity and enhancing its infrastructure, the company appears to be preparing to meet higher demand for its products.

Investors and industry observers will likely be watching closely to see how this expansion impacts Anuh Pharma's market position and financial performance in the coming quarters. The company's ability to utilize this additional capacity effectively could be a key factor in its future growth trajectory.

Anuh Pharma Limited has made this information available on its official website, demonstrating transparency in its communications with shareholders and the market at large.